Transition from Basal Bolus to Once-Weekly Subcutaneous Semaglutide and Basal Insulin in Patients with Type 2 Diabetes Mellitus (TRANSITION-T2D)-A Prospective Randomized Controlled Trial

被引：0
|
作者：
Rodriguez, Paloma
Breslaw, Nikki
Bena, James F.
Xiao, Huijun
Jenkins, Kimberly
Isaacs, Diana
Zhou, Keren
Griebeler, Marcio L.
Burguera, Barto
Pantalone, Kevin M.
机构：
来源：
DIABETES | 2023年 / 72卷
关键词：
D O I：
10.2337/db23-74-LB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
74-LB
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study
    Volpe, Sara
    Lisco, Giuseppe
    Fanelli, Margherita
    Racaniello, Davide
    Colaianni, Valentina
    Triggiani, Domenico
    Donghia, Rossella
    Crudele, Lucilla
    Rinaldi, Roberta
    Sabba, Carlo
    Triggiani, Vincenzo
    De Pergola, Giovanni
    Piazzolla, Giuseppina
    NUTRIENTS, 2022, 14 (21)
  • [42] Randomized Study Comparing a Basal-Bolus With a Basal Plus Correction Insulin Regimen for the Hospital Management of Medical and Surgical Patients With Type 2 Diabetes Basal Plus Trial
    Umpierrez, Guillermo E.
    Smiley, Dawn
    Hermayer, Kathie
    Khan, Amna
    Olson, Darin E.
    Newton, Christopher
    Jacobs, Sol
    Rizzo, Monica
    Peng, Limin
    Reyes, David
    Pinzon, Ingrid
    Fereira, Maria Eugenia
    Hunt, Vicky
    Gore, Ashwini
    Toyoshima, Marcos T.
    Fonseca, Vivian A.
    DIABETES CARE, 2013, 36 (08) : 2169 - 2174
  • [43] Effect of Once-Weekly Dulaglutide on Glucose Levels in Japanese Patients with Type 2 Diabetes: Findings from a Phase 4, Randomized Controlled Trial
    Inoue, Megumi
    Shiramoto, Masanari
    Oura, Tomonori
    Nasu, Risa
    Nakano, Masako
    Takeuchi, Masakazu
    DIABETES THERAPY, 2019, 10 (03) : 1019 - 1027
  • [44] Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Shi, Fang-Hong
    Li, Hao
    Cui, Min
    Zhang, Zai-Li
    Gu, Zhi-Chun
    Liu, Xiao-Yan
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [45] Effect of Once-Weekly Dulaglutide on Glucose Levels in Japanese Patients with Type 2 Diabetes: Findings from a Phase 4, Randomized Controlled Trial
    Megumi Inoue
    Masanari Shiramoto
    Tomonori Oura
    Risa Nasu
    Masako Nakano
    Masakazu Takeuchi
    Diabetes Therapy, 2019, 10 : 1019 - 1027
  • [46] Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial
    Koivisto, V.
    Cleall, S.
    Pontiroli, A. E.
    Giugliano, D.
    DIABETES OBESITY & METABOLISM, 2011, 13 (12): : 1149 - 1157
  • [47] Stepwise intensification of prandial insulin versus basal-bolus insulin therapy in patients with type 2 diabetes mellitus
    Raccah, D.
    Haak, T.
    Huet, D.
    Monnier, L.
    Ramon, J. S.
    Robertson, D.
    Labard, P.
    Penfornis, A.
    DIABETOLOGIA, 2010, 53
  • [48] Efficacy and Safety of Once-Weekly Semaglutide 2.0 vs. 1.0 mg for Type 2 Diabetes: SUSTAIN FORTE Randomized Trial
    Frias, Juan P.
    Auerbach, Pernille
    Bajaj, Harpreet S.
    Fukushima, Yasushi
    Lingvay, Ildiko
    Macura, Stanislava
    Sondergaard, Anette L.
    Tankova, Tsvetalina
    Tentolouris, Nikolaos
    Buse, John B.
    DIABETES, 2021, 70
  • [49] Efficacy and safety of adding once-weekly dulaglutide to basal insulin for inadequately controlled type 2 diabetes in Chinese patients (AWARD-CHN3): A randomized, double-blind, placebo-controlled, phase III trial
    Wang, Weimin
    Yan, Xin
    Cheng, Zhifeng
    Zhang, Qiqi
    Wang, Rui
    Deng, Yuying
    Ma, Jianhua
    Zhu, Dalong
    DIABETES OBESITY & METABOLISM, 2023, 25 (12): : 3690 - 3699
  • [50] Once-weekly basal insulin icodec offers comparable efficacy and safety vs once-daily insulin glargine U100 in insulin naive patients with type 2 diabetes inadequately controlled on OADs
    Rosenstock, J.
    Kjaersgaard, M.
    Moller, D.
    Hansen, M.
    Goldenberg, R.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S28 - S29
12345